The Jones Lab studies the biology of lung cancer metastases, with a focus on the breast cancer metastasis suppressor 1 (BRMS1) gene. Dr. Jones was the first to identify mechanisms governing the loss of BRMS1 and its resulting clinical significance in non-small cell lung cancer (NSCLC). The Jones laboratory has continued investigation into the role of BRMS1 in epithelial-mesenchymal transition, invasion and metastasis.
More recently, work in the Jones laboratory has identified adenosine deaminase acting on double-stranded RNA (ADAR) to be over expressed in a subset of lung adenocarcinoma, leading to a worse prognosis. Current work in the lab involves understanding the mechanism of ADAR’s action and identifying its target genes in lung adenocarcinoma.
David R. Jones, MD
Fiona and Stanley Druckenmiller Chair for Lung Cancer Research
Research FocusPhysician-scientist David R. Jones studies molecular mechanisms governing the development of metastases in lung and esophageal cancers.
- Liu Y, Mayo MW, Xiao A, et al. Loss of BRMS1 promotes a mesenchymal phenotype through NF-kappaB-dependent regulation of Twist1. Molecular and cellular biology. Jan 2015;35(1):303-317.
- Liu Y, Mayo MW, Nagji AS, et al. BRMS1 suppresses lung cancer metastases through an E3 ligase function on histone acetyltransferase p300. Cancer research. Feb 15 2013;73(4):1308-1317.
- AACR Career Development Award for Translational Research in Lung Cancer 2001
- Member, Tumor Progression and Metastases Study Section NCI; 2010-16 (Chair 2014-16)
- Co-Director, Fiona and Stanley Druckenmiller Center for Lung Cancer Research, MSKCC
- Castle Connolly Top Doctors for Cancer 2010-present